Tandem Diabetes Care (TNDM) Revenue Growth (5y) (2018 - 2026)
Tandem Diabetes Care (TNDM) Revenue Growth (5y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.88 Bn | 176.59 Bn | 6.27 Bn |
| 2 | Stryker | 128.94 Bn | 126.06 Bn | 3.81 Bn |
| 3 | Medtronic | 108.75 Bn | 99.53 Bn | 6.41 Bn |
| 4 | Boston Scientific | 68.65 Bn | 67.19 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.22 Bn | 44.55 Bn | 1.29 Bn |
| 6 | Dexcom | 28.43 Bn | 27.31 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 28.32 Bn | 26.03 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 26.91 Bn | 26.33 Bn | - |
| 9 | Koninklijke Philips | 25.10 Bn | 21.98 Bn | 2.07 Bn |
| 10 | Tandem Diabetes Care | 1.13 Bn | 564.45 Mn | 136.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.88% |
| Dec 31, 2025 | 11.56% |
| Sep 30, 2025 | 15.06% |
| Jun 30, 2025 | 17.12% |
| Mar 31, 2025 | 19.07% |
| Dec 31, 2024 | 21.13% |
| Sep 30, 2024 | 20.85% |
| Jun 30, 2024 | 18.93% |
| Mar 31, 2024 | 23.77% |
| Dec 31, 2023 | 20.90% |
| Sep 30, 2023 | 32.03% |
| Jun 30, 2023 | 41.84% |
| Mar 31, 2023 | 44.08% |
| Dec 31, 2022 | 40.49% |
| Sep 30, 2022 | 49.93% |
| Jun 30, 2022 | 56.51% |
| Mar 31, 2022 | 56.10% |
| Dec 31, 2021 | 48.67% |
| Sep 30, 2021 | 70.98% |
| Jun 30, 2021 | 49.58% |